Skip to content

Innoviva, Inc. INVA Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Organon logo
OrganonOGN
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Zymeworks logo
ZymeworksZYME
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Innoviva, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s payments to acquire intangible assets?
Innoviva, Inc. (INVA) reported payments to acquire intangible assets of $0 in Q4 2025.
How has Innoviva, Inc.'s payments to acquire intangible assets changed year-over-year?
Innoviva, Inc.'s payments to acquire intangible assets decreased by 100.0% year-over-year, from $1M to $0.